{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:25:51Z","timestamp":1794536751019,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04762-7","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:15:54Z","timestamp":1773450954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative efficacy of neoadjuvant short-course versus long-course radiotherapy-based regimens with or without immunotherapy for locally advanced pMMR rectal cancer: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Liqing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixiong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingshi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"28","key":"4762_CR1","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1200\/JCO.24.01160","volume":"42","author":"AJ Scott","year":"2024","unstructured":"Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, et al. Management of locally advanced rectal cancer: ASCO guideline. J Clin Oncol. 2024;42(28):3355\u201375.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4762_CR2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.annonc.2025.05.528","volume":"36","author":"RD Hofheinz","year":"2025","unstructured":"Hofheinz RD, Fokas E, Benhaim L, Price TJ, Arnold D, Beets-Tan R, et al. Localised rectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(9):1007\u201324.","journal-title":"Ann Oncol"},{"key":"4762_CR3","unstructured":"Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, et al. NCCN Guidelines(R) Insights: rectal cancer, version 3.2024. J Natl Compr Canc Netw. 2024;22(6):366\u201375."},{"issue":"1","key":"4762_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29\u201342.","journal-title":"Lancet Oncol"},{"issue":"15","key":"4762_CR5","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1200\/JCO.21.01667","volume":"40","author":"J Jin","year":"2022","unstructured":"Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40(15):1681\u201392.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4762_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.23.01208","volume":"42","author":"FS Verheij","year":"2024","unstructured":"Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT, et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol. 2024;42(5):500\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4762_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa2303269","volume":"389","author":"D Schrag","year":"2023","unstructured":"Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023;389(4):322\u201334.","journal-title":"N Engl J Med"},{"issue":"4","key":"4762_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/SLA.0000000000005780","volume":"277","author":"WJ Mei","year":"2023","unstructured":"Mei WJ, Wang XZ, Li YF, Sun YM, Yang CK, Lin JZ, et al. Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): initial results of a phase III trial. Ann Surg. 2023;277(4):557\u201364.","journal-title":"Ann Surg"},{"issue":"6","key":"4762_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO-24-01676","volume":"43","author":"J Zhang","year":"2025","unstructured":"Zhang J, Chi P, Shi L, Cui L, Gao J, Li W, et al. Neoadjuvant modified infusional fluorouracil, leucovorin, and oxaliplatin with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: updated results of the FOWARC study after a median follow-up of 10 years. J Clin Oncol. 2025;43(6):633\u201340.","journal-title":"J Clin Oncol"},{"key":"4762_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1515756","volume":"14","author":"W Pu","year":"2024","unstructured":"Pu W, Chen W, Jing H, Li J, Jiang Y, Li S, et al. Total neoadjuvant therapy based on short-course radiotherapy versus standard long-course chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis of randomized controlled trials. Front Oncol. 2024;14:1515756.","journal-title":"Front Oncol"},{"issue":"8","key":"4762_CR11","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/annonc\/mdz186","volume":"30","author":"B Cisel","year":"2019","unstructured":"Cisel B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 \u00d7 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30(8):1298\u2013303.","journal-title":"Ann Oncol"},{"issue":"5","key":"4762_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamapediatrics.2017.0057","volume":"171","author":"L Huang","year":"2017","unstructured":"Huang L, Yin Y, Yang L, Wang C, Li Y, Zhou Z. Comparison of antibiotic therapy and appendectomy for acute uncomplicated appendicitis in children: a meta-analysis. JAMA Pediatr. 2017;171(5):426\u201334.","journal-title":"JAMA Pediatr"},{"issue":"2","key":"4762_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3857\/roj.2020.00115","volume":"38","author":"M Aghili","year":"2020","unstructured":"Aghili M, Khalili N, Khalili N, Babaei M, Farhan F, Haddad P, et al. Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial. Radiat Oncol J. 2020;38(2):119\u201328.","journal-title":"Radiat Oncol J"},{"issue":"5","key":"4762_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bjs\/znab020","volume":"108","author":"D Chakrabarti","year":"2021","unstructured":"Chakrabarti D, Rajan S, Akhtar N, Qayoom S, Gupta S, Verma M, et al. Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial. Br J Surg. 2021;108(5):511\u201320.","journal-title":"Br J Surg"},{"issue":"1","key":"4762_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12029-023-00966-9","volume":"55","author":"A Amariyil","year":"2024","unstructured":"Amariyil A, Pathy S, Sharma A, Kumar S, Pramanik R, Bhoriwal S, et al. Randomized controlled trial of neoadjuvant short-course radiotherapy followed by consolidation chemotherapy versus long-course chemoradiotherapy in locally advanced rectal cancer: comparison of overall response rates. J Gastrointest Cancer. 2024;55(1):373\u201382.","journal-title":"J Gastrointest Cancer"},{"issue":"5","key":"4762_CR16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/annonc\/mdw062","volume":"27","author":"K Bujko","year":"2016","unstructured":"Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Krynski J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 \u00d7 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834\u201342.","journal-title":"Ann Oncol"},{"key":"4762_CR17","doi-asserted-by":"crossref","unstructured":"Liscu HD, Verga N, Atasiei DI, Ilie AT, Vrabie M, Rosu L, et al. Therapeutic management of locally advanced rectal cancer: existing and prospective approaches. J Clin Med. 2025;14(3):912.","DOI":"10.3390\/jcm14030912"},{"issue":"5","key":"4762_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL, Rio E, Francois E, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702\u201315.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4762_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361\u201375.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"4762_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. <article-title update=\"added\">Durable clinical benefit with Nivolumab plus Ipilimumab in DNA mismatch repair\u2013deficient\/microsatellite instability\u2013high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773\u20139.","journal-title":"J Clin Oncol"},{"key":"4762_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1440830","volume":"15","author":"Q Wang","year":"2024","unstructured":"Wang Q, Yu M, Zhang S. The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies. Front Immunol. 2024;15:1440830.","journal-title":"Front Immunol"},{"issue":"7","key":"4762_CR22","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1007\/s12094-023-03091-y","volume":"25","author":"C Wu","year":"2023","unstructured":"Wu C, Shao Y, Gu W. Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer. Clin Transl Oncol. 2023;25(7):1916\u201328.","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"4762_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41571-024-00943-6","volume":"21","author":"CJM Williams","year":"2024","unstructured":"Williams CJM, Peddle AM, Kasi PM, Seligmann JF, Roxburgh CS, Middleton GW, et al. Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response. Nat Rev Clin Oncol. 2024;21(12):839\u201351.","journal-title":"Nat Rev Clin Oncol"},{"key":"4762_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100807","author":"Y Tang","year":"2025","unstructured":"Tang Y, Li HY, Wei LC, Li N, Zhang WJ, Lu YF, et al. Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: phase 2 results of a randomized trial (STELLAR II). Med. 2025. https:\/\/doi.org\/10.1016\/j.medj.2025.100807.","journal-title":"Med"},{"issue":"8","key":"4762_CR25","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S1470-2045(25)00286-4","volume":"26","author":"F Tian","year":"2025","unstructured":"Tian F, Dai H, Sha D, Yu Y, Jing H, Sun C, et al. Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial. Lancet Oncol. 2025;26(8):1043\u201354.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4762_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41591-024-03360-5","volume":"31","author":"Y Yang","year":"2025","unstructured":"Yang Y, Pang K, Lin G, Liu X, Gao J, Zhou J, et al. Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial. Nat Med. 2025;31(2):449\u201356.","journal-title":"Nat Med"},{"issue":"8","key":"4762_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.27769","volume":"8","author":"J Laengle","year":"2025","unstructured":"Laengle J, Kuehrer I, Kulu A, Kabiljo J, Ammon D, Zirnbauer R, et al. Dual immune checkpoint inhibition plus neoadjuvant chemoradiotherapy in rectal cancer: a randomized clinical trial. JAMA Netw Open. 2025;8(8):e2527769.","journal-title":"JAMA Netw Open"},{"key":"4762_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020465","author":"QR Bao","year":"2023","unstructured":"Bao QR, Ferrari S, Capelli G, Ruffolo C, Scarpa M, Agnes A, et al. Rectal sparing approaches after neoadjuvant treatment for rectal cancer: a systematic review and meta-analysis comparing local excision and watch and wait. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15020465.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"4762_CR29","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","volume":"35","author":"ZY Lin","year":"2024","unstructured":"Lin ZY, Zhang P, Chi P, Xiao Y, Xu XM, Zhang AM, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial. Ann Oncol. 2024;35(10):882\u201391.","journal-title":"Ann Oncol"},{"issue":"8","key":"4762_CR30","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","volume":"7","author":"OE Rahma","year":"2021","unstructured":"Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(8):1225\u201330.","journal-title":"JAMA Oncol"},{"issue":"9","key":"4762_CR31","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ccell.2024.07.004","volume":"42","author":"WW Xiao","year":"2024","unstructured":"Xiao WW, Chen G, Gao YH, Lin JZ, Wu XJ, Luo HL, et al. Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial. Cancer Cell. 2024;42(9):1570-81 e4.","journal-title":"Cancer Cell"},{"issue":"28","key":"4762_CR32","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1200\/JCO.23.02261","volume":"42","author":"F Xia","year":"2024","unstructured":"Xia F, Wang Y, Wang H, Shen L, Xiang Z, Zhao Y, et al. Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH). J Clin Oncol. 2024;42(28):3308\u201318.","journal-title":"J Clin Oncol"},{"key":"4762_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115428","volume":"222","author":"A Shamseddine","year":"2025","unstructured":"Shamseddine A, Turfa R, Chehade L, Zeidan YH, El Husseini Z, Kreidieh M, et al. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: the Averectal study. Eur J Cancer. 2025;222:115428.","journal-title":"Eur J Cancer"},{"key":"4762_CR34","doi-asserted-by":"crossref","unstructured":"Jianhong P, Chi Z, Miaozhen Q, Weihao L, Qiaoxuan W, Min L, et al. Phase II trial of anti PD-1 monoclonal antibody and FOLFOXIRI combined with longcourse radiotherapy as the total neoadjuvant treatment for proficient mismatch repair, locally advanced, low rectal cancer (PANFORTE). J Clin Oncol. 2025;43(16_suppl):e15621.","DOI":"10.1200\/JCO.2025.43.16_suppl.e15621"},{"issue":"1","key":"4762_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41698-025-01018-0","volume":"9","author":"Z Hou","year":"2025","unstructured":"Hou Z, Liao L, Xiao W, Sui Q, Han K, Xiao B, et al. Neoadjuvant chemoradiotherapy plus sintilimab in pMMR\/MSS rectal cancer patients with PD-L1 TPS >\/= 1% or CPS >\/= 1: an open-label, prospective, phase II study. NPJ Precis Oncol. 2025;9(1):237.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"4762_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01762-y","volume":"9","author":"Z Yang","year":"2024","unstructured":"Yang Z, Gao J, Zheng J, Han J, Li A, Liu G, et al. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study. Signal Transduct Target Ther. 2024;9(1):56.","journal-title":"Signal Transduct Target Ther"},{"key":"4762_CR37","unstructured":"Xuan Z, Feng Q, Cai X, Yu K, Shen T, Pan D, Li Y. Preliminary effi cacy and safety of total neoadjuvant therapy combined with PD-L1 blockade in pMMR\/MSS locally advanced rectal cancer (ESTIMATE): a prospective, single-arm, phase II trial. Xiamen, China: Poster presented at: 27th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO); 2024."},{"issue":"1","key":"4762_CR38","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/JS9.0000000000001960","volume":"111","author":"F Wang","year":"2024","unstructured":"Wang F, Lai C, Lv Y, Zhang F, Shi L, Wang Y, et al. Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study. Int J Surg. 2024;111(1):334\u201345.","journal-title":"Int J Surg"},{"key":"4762_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.259","author":"X Liu","year":"2024","unstructured":"Liu X, He L, Tong W, Li S, Wang Z, Gu M. Neoadjuvant chemoradiotherapy plus PD-1 blockade for high or very high-risk locally advanced rectal cancer. Ann Oncol. 2024. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.259.","journal-title":"Ann Oncol"},{"issue":"5","key":"4762_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamasurg.2023.7996","volume":"159","author":"Y Li","year":"2024","unstructured":"Li Y, Pan C, Gao Y, Zhang L, Ji D, Cui X, et al. Total neoadjuvant therapy with PD-1 blockade for high-risk proficient mismatch repair rectal cancer. JAMA Surg. 2024;159(5):529\u201337.","journal-title":"JAMA Surg"},{"key":"4762_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.256","author":"L Feng","year":"2024","unstructured":"Feng L, Tang Y, Zhang W, Xu T, Li H, Ma H. The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and cadonilimab for locally advanced rectal cancer: the preliminary findings of prospective, multicenter phase II trial. Ann Oncol. 2024. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.256.","journal-title":"Ann Oncol"},{"issue":"5","key":"4762_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101824","volume":"8","author":"E Grassi","year":"2023","unstructured":"Grassi E, Zingaretti C, Petracci E, Corbelli J, Papiani G, Banchelli I, et al. Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial. ESMO Open. 2023;8(5):101824.","journal-title":"ESMO Open"},{"key":"4762_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1057947","volume":"13","author":"J Gao","year":"2023","unstructured":"Gao J, Zhang X, Yang Z, Zhang J, Bai Z, Deng W, et al. Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer. Front Oncol. 2023;13:1057947.","journal-title":"Front Oncol"},{"key":"4762_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1790","author":"J Carrasco","year":"2023","unstructured":"Carrasco J, Beniuga G, Jouret-Mourin A, Baldin P, Sinapi I, Schroeder D. R-IMMUNE: a phase Ib\/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC). Ann Oncol. 2023. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1790.","journal-title":"Ann Oncol"},{"key":"4762_CR45","doi-asserted-by":"publisher","first-page":"S430","DOI":"10.1016\/j.annonc.2023.09.1786","volume":"34","author":"J Capdevila Castillon","year":"2023","unstructured":"Capdevila Castillon J, Alonso V, Macias Declara I, Melian M, Gallego Plazas J, Vera R, et al. The DUREC trial: durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703). Ann Oncol. 2023;34:S430\u20131.","journal-title":"Ann Oncol"},{"key":"4762_CR46","doi-asserted-by":"crossref","unstructured":"Thomas J, George GY, Samuel AJ, Gene GF, James LW, Caio, Max SPRLJSR, Shalu P, Anuradha K, John C, Krauss MD, Jesus CF, James JL, Carmen JA, Norman, Wolmark. Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2. J Clin Oncol. 2022;40(4_suppl):99.","DOI":"10.1200\/JCO.2022.40.4_suppl.099"},{"issue":"6","key":"4762_CR47","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","volume":"28","author":"H Bando","year":"2022","unstructured":"Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, et al. Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability\u2013high locally advanced rectal cancer. Clin Cancer Res. 2022;28(6):1136\u201346.","journal-title":"Clin Cancer Res"},{"key":"4762_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.016","author":"L Salvatore","year":"2021","unstructured":"Salvatore L, Bensi M, Corallo S, Bergamo F, Pellegrini I, Rasola C. Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: the AVANA study. Ann Oncol. 2021. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.016.","journal-title":"Ann Oncol"},{"key":"4762_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003554","author":"Z Lin","year":"2021","unstructured":"Lin Z, Cai M, Zhang P, Li G, Liu T, Li X, et al. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-003554.","journal-title":"J Immunother Cancer"},{"issue":"765","key":"4762_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk0642","volume":"16","author":"JC Jagodinsky","year":"2024","unstructured":"Jagodinsky JC, Vera JM, Jin WJ, Shea AG, Clark PA, Sriramaneni RN, et al. Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade. Sci Transl Med. 2024;16(765):eadk0642.","journal-title":"Sci Transl Med"},{"issue":"11","key":"4762_CR51","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/jnci\/djad118","volume":"115","author":"L Karapetyan","year":"2023","unstructured":"Karapetyan L, Iheagwara UK, Olson AC, Chmura SJ, Skinner HK, Luke JJ. Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations. J Natl Cancer Inst. 2023;115(11):1278\u201393.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"4762_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70346","volume":"6","author":"X Wang","year":"2025","unstructured":"Wang X, Jing J. Cancer immunotherapy in combination with radiotherapy and\/or chemotherapy: mechanisms and clinical therapy. MedComm. 2025;6(9):e70346.","journal-title":"MedComm"},{"issue":"4","key":"4762_CR53","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","volume":"83","author":"D Schaue","year":"2012","unstructured":"Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1306\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4762_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/biom14040448","author":"IM Koukourakis","year":"2024","unstructured":"Koukourakis IM, Xanthopoulou E, Koukourakis MI, Tiniakos D, Kouloulias V, Zygogianni A. IFN-type-I response and systemic immunity in rectal adenocarcinoma patients treated with conventional or hypofractionated neoadjuvant radiotherapy. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/biom14040448.","journal-title":"Biomolecules"},{"issue":"9","key":"4762_CR55","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1339857","volume":"6","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Formenti SC, Demaria S. TREX1 dictates the immune fate of irradiated cancer cells. Oncoimmunology. 2017;6(9):e1339857.","journal-title":"Oncoimmunology"},{"key":"4762_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.612072","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang Y. Advances in hypofractionated irradiation-induced immunosuppression of tumor microenvironment. Front Immunol. 2020;11:612072.","journal-title":"Front Immunol"},{"issue":"8","key":"4762_CR57","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","volume":"20","author":"L Galluzzi","year":"2023","unstructured":"Galluzzi L, Aryankalayil MJ, Coleman CN, Formenti SC. Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023;20(8):543\u201357.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"4762_CR58","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41416-023-02459-9","volume":"129","author":"IM Koukourakis","year":"2023","unstructured":"Koukourakis IM, Xanthopoulou E, Sgouras TI, Kouroupi M, Giatromanolaki A, Kouloulias V, et al. Preoperative chemoradiotherapy induces multiple pathways related to anti-tumour immunity in rectal cancer. Br J Cancer. 2023;129(11):1852\u201362.","journal-title":"Br J Cancer"},{"issue":"6","key":"4762_CR59","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1080\/09553002.2024.2331115","volume":"100","author":"J Boustani","year":"2024","unstructured":"Boustani J, Lecoester B, Baude J, Latour C, Limagne E, Ladjohoulou R, et al. Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model. Int J Radiat Biol. 2024;100(6):912\u201321.","journal-title":"Int J Radiat Biol"},{"issue":"6","key":"4762_CR60","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00066-018-1287-1","volume":"194","author":"M Ruckert","year":"2018","unstructured":"Ruckert M, Deloch L, Fietkau R, Frey B, Hecht M, Gaipl US. Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. Strahlenther Onkol. 2018;194(6):509\u201319.","journal-title":"Strahlenther Onkol"},{"key":"4762_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1105180","volume":"14","author":"J Shi","year":"2023","unstructured":"Shi J, Sun Z, Gao Z, Huang D, Hong H, Gu J. Radioimmunotherapy in colorectal cancer treatment: present and future. Front Immunol. 2023;14:1105180.","journal-title":"Front Immunol"},{"key":"4762_CR62","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.trsl.2020.12.002","volume":"231","author":"EE Otegbeye","year":"2021","unstructured":"Otegbeye EE, Mitchem JB, Park H, Chaudhuri AA, Kim H, Mutch MG, et al. Immunity, immunotherapy, and rectal cancer: a clinical and translational science review. Transl Res. 2021;231:124\u201338.","journal-title":"Transl Res"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04762-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04762-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04762-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:02:09Z","timestamp":1776823329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04762-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4762"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04762-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have given their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}